Ebb & Flow

The $30 million series B round by cardiovascular gene therapy play Celladon is not a harbinger of open purse strings for gene delivery companies. Instead, Celladon and its seasoned VC investors maintain that biology is the selling proposition, and that gene therapy happens to suit the pathway the company is focused on.

Investors in the B round were Kleiner Perkins Caufield & Byers and Domain Associates, which were joined by existing investors Enterprise Partners and Venrock. Clearly the group has been around the industry for many years and has seen gene therapy companies come and go. ...